Company news
Shouyao Holdings Beijing Co. Ltd. Class A (SSE:688197) news
Shouyao Holdings Beijing Co. Ltd. Class A news releases on 6ix. Latest, Sep 24, 2026: "SHOUYAO HOLDINGS CO., LTD."Indicative Announcement on Listing…
Press releases & updates
"SHOUYAO HOLDINGS CO., LTD."Indicative Announcement on Listing and Trading of Restricted Shares from the Initial Public Offering
September 23, 2026
"SHOUYAO HOLDINGS CO., LTD."Semi-annual Report for 2026
August 28, 2026
"SHOUYAO HOLDINGS CO., LTD."Announcement on Signing of the General Construction Contract and Progress of External Investment
August 25, 2026
"SHOUYAO HOLDINGS CO., LTD."Announcement on Change of Sponsor Representative for Continuous Supervision
August 4, 2026
"SHOUYAO HOLDINGS CO., LTD."Announcement on the Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Fourth-generation ALK Inhibitor SY-12321
July 16, 2026
"SHOUYAO HOLDINGS CO., LTD."Announcement on Completion of Industrial and Commercial Registration Changes and Renewal of Business License
July 6, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 26, 2026
Announcement on Voluntary Disclosure of Approval of ALK Inhibitor Conteltinib Granules (Shouyaoze®) for Marketing by the National Medical Products Administration
June 11, 2026
Announcement on Resolutions of the 14th Meeting of the 2nd Board of Directors
June 5, 2026
Announcement on Expanding Business Scope, Amending the Articles of Association and Handling Industrial and Commercial Change Registration
April 17, 2026
Announcement on the Adjustment of the Collaborative R&D Model for JAK2 Inhibitor Antitumor New Drugs
March 4, 2026
Announcement on Resignation of Director
February 27, 2026
Announcement on Retirement and Resignation of Core Technical Personnel
February 12, 2026
Announcement on Voluntary Disclosure of MAT2A Inhibitor SY-9453 Obtaining the Notice of Approval for Drug Clinical Trials
February 4, 2026
Preliminary Earnings Estimate for 2025
January 30, 2026
Announcement on Obtaining Government Subsidies
December 24, 2025
Report for Q3 2025
October 30, 2025
Announcement on Voluntary Disclosure of Acceptance of the New Drug Application for Marketing of the RET Inhibitor Sotolitinib Tablets (SY-5007)
October 22, 2025
Announcement on Completing Industrial and Commercial Change Registration and Filing, as well as Obtaining Renewed "Business License"
October 17, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 15, 2025
Semi-annual Evaluation Report on "Corporate Value and Return Enhancement" Action Plan 2025
August 27, 2025
Announcement on Using Self-owned Funds to Pay Some Funds for Raised Fund Investment Projects and Replacing Them with an Equal Amount of Raised Funds
June 20, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Using Temporarily Idle Raised Funds for Cash Management
April 27, 2025
Announcement on Listing and Circulation of Some Restricted Stocks in Initial Public Offering
March 14, 2025
Announcement on 2024 Annual Preliminary Earnings Estimate
January 17, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2024
December 26, 2024
Announcement on Resolution of the 7th Meeting of the 2nd Board of Directors
December 10, 2024
Announcement on Voluntary Disclosure of Adjustment to the Development Strategy of BTK Inhibitor SY-1530
November 6, 2024
Report for Q3 2024
October 27, 2024
Announcement on Voluntary Disclosure of the Acceptance of New Drug Application for the ALK inhibitor Conteltinib (CT-707)
October 22, 2024
Announcement on Participating in the 2024 Semi-annual Pharmaceutical and Biological Products Collective Performance Briefing
September 8, 2024
Semi-annual Evaluation Report on "Corporate Value and Return Enhancement" Action Plan 2024
August 25, 2024
Announcement on Convening Performance Meeting for 2023 and 1st Quarter of 2024
June 7, 2024
Announcement on Resolutions of 2023 Annual General Meeting
May 29, 2024
Indicative Announcement on Report on Result of Shareholder' Inquiry Transfer, and Equity Changes of Shareholding Reduction by Shareholder with Over 5% Shares by 1% and Shareholding Reduction to Less than 5%
May 24, 2024
Indicative Announcement on Pricing of Shareholders' Inquiry Transfer
May 20, 2024
Notice on Convening 2023 Annual General Meeting
May 5, 2024
Announcement on Amending "Articles of Association" and Formulating and Amending Some Governance Systems
April 28, 2024
Announcement on Resignation of Independent Director
April 17, 2024
Announcement on Circulation of Restricted Shares under Strategic Allotment in Initial Public Offering
March 15, 2024
Announcement on Abnormal Fluctuation of Stock Trading
March 14, 2024
Announcement on 2023 Annual Preliminary Earnings Estimate
January 30, 2024
Announcement on Voluntary Disclosure of Obtaining Report on Ethical Approval for Key Phase III Clinical Trials of 3rd-generation ALK Kinase Inhibitor SY-3505
December 25, 2023
Announcement on Convening 2023 3rd Quarter Performance Meeting
October 30, 2023
Announcement on Resolution of 1st Special Shareholders' Meeting of 2023
September 20, 2023
Announcement on Circulation of Some Restricted Shares in Initial Public Offering
September 18, 2023
Notice on Convening 1st Special Shareholders' Meeting of 2023
September 1, 2023